• Alkermes plc, of Dublin, Ireland, reported top-line results from a 32-patient Phase I/II study, showing that ALKS 5461 was able to significantly reduce depressive symptoms in subjects with major depressive disorder (MDD), as measured by the Hamilton Depression Rating Scale. Patients in the study received ALKS 5461, a combination of an opioid modulator and buprenorphine, over a seven-day treatment period.